TKT抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P08901(TKT Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P08901(TKT Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

**Background of TKT Antibodies**

Thiamine kinase (TKT) is an enzyme critical to the pentose phosphate pathway (PPP), a metabolic route essential for nucleotide synthesis, redox balance, and carbon skeleton production. TKT catalyzes the transfer of a two-carbon ketol group between sugar phosphates, linking glycolysis to PPP and supporting cellular biosynthesis. Dysregulation of TKT activity has been implicated in metabolic disorders, cancer, and diabetic complications, where altered glucose metabolism drives disease progression.

TKT antibodies are immunological tools developed to detect and quantify TKT expression in research and diagnostics. They enable the study of TKT's role in metabolic reprogramming, particularly in cancer cells that rely on PPP for rapid proliferation and antioxidant defense. In diabetes, TKT overexpression has been linked to advanced glycation end product (AGE)-induced pathologies, such as neuropathy and nephropathy.

These antibodies, often monoclonal or polyclonal, are validated for techniques like Western blotting, immunohistochemistry, and ELISA. Recent studies explore TKT as a potential therapeutic target, with inhibitors under investigation for anticancer applications. The development of highly specific TKT antibodies has advanced understanding of metabolic adaptations in disease, highlighting their value in both basic research and translational medicine. Ongoing efforts focus on optimizing antibody sensitivity and cross-reactivity across species to support broader biomedical applications.